Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Study suggests bacterial products contribute to autoimmune diseases

Study suggests bacterial products contribute to autoimmune diseases

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

New global event focuses on childhood psoriasis

New global event focuses on childhood psoriasis

IPC investigating relationship between BMI and severity of psoriasis in childhood

IPC investigating relationship between BMI and severity of psoriasis in childhood

Survey highlights emotional impact of psoriasis on school children

Survey highlights emotional impact of psoriasis on school children

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

PCE, NPF form partnership to provide education programs on psoriasis

PCE, NPF form partnership to provide education programs on psoriasis

Discovery may aid in developing new psoriasis therapies

Discovery may aid in developing new psoriasis therapies

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Researchers receive BioBank DNA samples to unveil psoriasis genetics

Researchers receive BioBank DNA samples to unveil psoriasis genetics

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

DermaGenoma announces availability of PsoriasisDX Genetic Test as CE Marked product for PsA

DermaGenoma announces availability of PsoriasisDX Genetic Test as CE Marked product for PsA

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Twelve residents receive one-year fellowship grant to study medical dermatology

Twelve residents receive one-year fellowship grant to study medical dermatology